WhaleCreep

Casdin Capital, LLC 13F holdings, Q1 2016

Hedge fundSEC filingsCompare with another fundHoldings as of 2016-03-31, filed 2016-05-09

Casdin Capital, LLC disclosed 25 US equity positions worth $84.5m in its Q1 2016 13F filing. Its largest position is LOXO ONCOLOGY INC at 8.1% of the reported book, followed by EPZMEUR and FOUNDATION MEDICINE INC. Versus Q4 2015 it opened 5 new positions, added to 12, reduced 6 and exited 7.

$84.5m
Reported equity book
Sum of the long US equity positions in the filing, at the values filed. Options are excluded.
25
Positions
Distinct securities in the equity book with a reported value above zero. Options are excluded.
8.1%
Largest position
The largest single position as a share of the reported equity book.
68.9%
Top 10 weight
The ten largest positions together, as a share of the reported equity book.
17
Effective positions
1 / HHI of portfolio weights: the number of equal-weight positions the book behaves like.
43
Quarters on file since Q4 2015
Quarters for which this manager's 13F holdings are on record.

Holdings

Against Q4 2015: 5 new, 12 added, 6 reduced, 7 exited

25 rows
LOXO ONCOLOGY INC no ticker–8.1%$6.8m250,000−0.6%reduced
EPZMEUR EPIZYME INC–7.8%$6.6m545,000+64%added
FOUNDATION MEDICINE INC no ticker–7.2%$6.1m335,000+191%added
SG7 SAGE THERAPEUTICS INC–7.2%$6.1m189,000+32%added
AGIO AGIOS PHARMACEUTICALS INCHealthcare7.1%$6.0m148,000+53%added
2655787D BLUEPRINT MEDICINES CORP–6.9%$5.8m321,300−22%reduced
ALNY ALNYLAM PHARMACEUTICALS INCHealthcare6.7%$5.6m90,000+50%added
BLUEBIRD BIO INC no ticker–6.0%$5.1m120,000+20%added
MYOKEUR MYOKARDIA INC–6.0%$5.1m475,350+18%added
ONCEEUR SPARK THERAPEUTICS INC–5.9%$5.0m170,000+17%added
CTMX CYTOMX THERAPEUTICS INC.Healthcare4.9%$4.1m321,0230.0%held
KITE PHARMA INC no ticker–4.1%$3.4m75,000+150%added
VYGR VOYAGER THERAPEUTICS INCHealthcare3.5%$3.0m339,362+43%added
EDIT EDITAS MEDICINE INCHealthcare3.5%$3.0m85,470–new
DXCM DEXCOM INCHealthcare3.2%$2.7m40,000+135%added
AVEXIS INC no ticker–2.0%$1.7m63,000–new
GBTUSD GLOBAL BLOOD THERAPEUTICS IN–2.0%$1.7m105,000+62%added
GHDX GENOMIC HEALTH INC–1.6%$1.4m55,000−67%reduced
BMY BRISTOL-MYERS SQUIBB COHealthcare1.6%$1.3m21,000−35%reduced
BIIB BIOGEN INCHealthcare1.5%$1.3m5,000−44%reduced
ONC BEIGENE LTDHealthcare1.1%$953k32,500–new
IGNYTA INC no ticker–0.9%$745k110,000–new
EXK EXACT SCIENCES CORPBasic Materials0.5%$404k60,000–new
MDSOEUR MEDIDATA SOLUTIONS INC–0.5%$387k10,0000.0%held
OXFORD IMMUNOTEC GLOBAL PLC no ticker–0.2%$198k20,000−73%reduced

Exited since Q4 2015

7 rows
ILMN ILLUMINA INC5.4%$5.8m
GNMK GENMARK DIAGNOSTICS INC2.2%$2.4m
NVTA1EUR INVITAE CORP1.9%$2.1m
OSUR ORASURE TECHNOLOGIES INC1.0%$1.1m
JUNO THERAPEUTICS INC no ticker0.7%$769k
ATRA ATARA BIOTHERAPEUTICS INC0.6%$660k
TROVAGENE INC no ticker0.4%$378k

Sector mix

  • Unclassified66.4%
  • Healthcare33.2%
  • Basic Materials0.5%

Book over time

Every quarter on file (43)
QuarterPositionsEquity book
Q2 202643$2.0bn
Q1 202640$1.3bn
Q4 202538$1.6bn
Q3 202532$1.2bn
Q2 202533$1.1bn
Q1 202544$1.2bn
Q4 202438$1.5bn
Q3 202435$1.5bn
Q2 202438$1.3bn
Q1 202436$1.3bn
Q4 202336$1.0bn
Q3 202338$897m
Q2 202341$1.1bn
Q1 202340$1.2bn
Q4 202244$1.3bn
Q3 202236$1.5bn
Q2 202240$1.2bn
Q1 202247$2.2bn
Q4 202153$3.5bn
Q3 202153$4.0bn
Q2 202154$3.9bn
Q1 202148$3.4bn
Q4 202050$3.4bn
Q3 202045$2.2bn
Q2 202042$1.7bn
Q1 202038$942m
Q4 201931$1.1bn
Q3 201933$966m
Q2 201931$1.1bn
Q1 201929$910m
Q4 201831$585m
Q3 201834$814m
Q2 201832$709m
Q1 201830$565m
Q4 201726$409m
Q3 201726$354m
Q2 201731$250m
Q1 201729$170m
Q4 201625$121m
Q3 201626$123m
Q2 201624$95.7m
Q1 201625$84.5m
Q4 201527$107m

Where Casdin Capital, LLC was early

41 rows
EDIT EDITAS MEDICINE INCQ1 20162 of 963.5%3.5%15Held at last filing, Q2 2026−91%
ONC BEIGENE LTDQ1 20169 of 1041.1%2.1%16Exited by Q2 2025+829%
EVH EVOLENT HEALTH INCQ2 20161 of 1304.8%7.7%12Exited by Q2 2019−34%
T8S TESARO INCQ2 20168 of 831.8%2.7%4Exited by Q4 2017+54%
MDRX ALLSCRIPTS HEALTHCARE SOLUTNQ3 20168 of 962.1%2.4%3Exited by Q2 2017−3.7%
CDXS CODEXIS INCQ1 20172 of 801.9%8.1%29Exited by Q3 2025−49%
PACB PACIFIC BIOSCIENCES CALIF INQ1 20173 of 1182.1%5.1%21Held at last filing, Q2 2026−68%
SGMOQ SANGAMO THERAPEUTICS INCQ1 20173 of 852.6%5.9%19Exited by Q3 2022−20%
FATE FATE THERAPEUTICS INCQ2 20174 of 1070.7%8.3%27Exited by Q1 2024+15%
CRSP CRISPR THERAPEUTICS AGQ1 20181 of 1201.1%1.8%11Exited by Q1 2022+66%
ZLAB ZAI LAB LTDQ1 20186 of 990.5%1.0%11Exited by Q2 2022+106%
BLFS BIOLIFE SOLUTIONS INCQ2 20181 of 781.6%16.3%33Held at last filing, Q2 2026+148%
CDNA CAREDX INCQ2 20186 of 1030.3%3.0%16Exited by Q2 2022+202%
CNST CONSTELLATION PHARMCETICLS IQ3 20181 of 721.1%5.3%12Exited by Q3 2021–
2JQ GRITSTONE ONCOLOGY INCQ3 20182 of 621.3%1.9%8Exited by Q3 2020−53%
SRPT SAREPTA THERAPEUTICS INCQ3 201814 of 1820.8%13.7%29Held at last filing, Q2 2026−89%
DNLI DENALI THERAPEUTICS INCQ4 20182 of 1040.4%3.7%31Held at last filing, Q2 2026+24%
ALEC ALECTOR INCQ1 20194 of 870.7%2.8%12Exited by Q1 2022+10%
TWST TWIST BIOSCIENCE CORPQ2 20192 of 990.8%4.2%17Exited by Q3 2023−29%
ADPT ADAPTIVE BIOTECHNOLOGIES CORQ2 20194 of 1301.9%2.3%12Exited by Q2 2022−71%
FULC FULCRUM THERAPEUTICS INCQ3 20191 of 950.6%1.9%8Exited by Q3 2021+58%
RVMD REVOLUTION MEDICINES INCQ1 20201 of 1643.1%24.2%26Held at last filing, Q2 2026+755%
DMTKQ DERMTECH INCQ1 20202 of 470.6%2.6%9Exited by Q2 2022+31%
ALLO ALLOGENE THERAPEUTICS INCQ1 20204 of 941.0%1.6%8Exited by Q1 2022−23%
GBIOGBX GENERATION BIO COQ2 20201 of 482.0%2.2%8Exited by Q2 2022−65%
RLAY RELAY THERAPEUTICS INCQ3 20201 of 1117.3%15.0%24Held at last filing, Q2 2026−56%
FDMT 4D MOLECULAR THERAPEUTICS INQ4 20201 of 941.0%2.1%16Exited by Q1 2025−87%
BEAM BEAM THERAPEUTICS INCQ4 20203 of 981.1%3.2%23Held at last filing, Q2 2026−58%
ABCL ABCELLERA BIOLOGICS INCQ4 20207 of 870.2%1.8%9Exited by Q2 2024−89%
IPSC CENTURY THERAPEUTICS INCQ2 20213 of 512.4%2.4%21Held at last filing, Q2 2026−92%
TNYA TENAYA THERAPEUTICS INCQ3 20211 of 531.8%3.3%20Held at last filing, Q2 2026−96%
ABSI ABSCI CORPORATIONQ3 20212 of 762.2%2.9%20Held at last filing, Q2 2026−0.3%
MXCT MAXCYTE INCQ3 20212 of 634.3%5.6%9Exited by Q4 2023−74%
TNGX TANGO THERAPEUTICS INCQ3 20212 of 1031.8%1.9%13Exited by Q2 2025−89%
WGS GENEDX HOLDINGS CORPQ3 20215 of 1040.9%29.5%20Held at last filing, Q2 2026−73%
TSVT* 2SEVENTY BIO INCQ1 20224 of 700.5%1.8%13Exited by Q2 2025−71%
PLRX PLIANT THERAPEUTICS INCQ3 20228 of 1031.0%3.7%8Exited by Q3 2024−49%
PRME PRIME MEDICINE INCQ4 20223 of 621.1%1.5%15Held at last filing, Q2 2026−80%
GPCR STRUCTURE THERAPEUTICS INCQ1 20231 of 1141.3%6.9%14Held at last filing, Q2 2026+126%
NGNE NEUROGENE INCQ4 20232 of 451.0%2.4%11Held at last filing, Q2 2026+62%
MAZE MAZE THERAPEUTICS INCQ1 20259 of 820.9%2.0%6Held at last filing, Q2 2026+171%

Concentration and tenure

12.9%
Median largest position, all quarters
The largest single position as a share of the reported equity book.
65.0%
Median top 10 weight, all quarters
The ten largest positions together, as a share of the reported equity book.
Concentrated
Style, by median largest position
3
Median completed holding, quarters